Drugs / Ad26.Filo
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02860650 | Aug 2016 → May 2017 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad26.Filo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02860650 ↗ |
| Modality | Vaccine | “Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules” NCT02860650 ↗ |
| Route | Intramuscular | “Ad26.Filo intramuscular (IM) injection” NCT02860650 ↗ |